Genocea Biosciences (GNCA) Q2 results:
Revenues: $0.9M.
Net loss: ($11.3M) (-73.8%); loss/share: ($0.39) (+7.1%); Quick Assets: $22.1M (-44.9%).
GNCA presented long-term follow-up data from Part A of the ongoing Phase 1/2a clinical trial of GEN-009 at ASCO20 Virtual Scientific Program that evaluates eight participants.
Seven out of eight patients treated on Part A of the study are without disease progression at one-year median follow-up.
ATLAS-identified neoantigens generate broad, sustained T cell responses starting after only 4 weeks and lasting for up to 1 year after the last vaccination.
Genocea will present a clinical update on GEN-009 on July 30, at 8:00 a.m. EDT.
The company has filed an IND application to initiate a Phase 1/2a study of GEN-011 evaluating patient safety, T cell proliferation and persistence, and clinical activity. The trial expects to enroll up to 24 patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.